There are a number of companies that facilitate the development of induced pluripotent stem cell (iPSC) therapies, including Cellular Dynamics International (CDI), Ocata Therapeutics, RIKEN, and Cynata Therapeutics. Cynata is unique in its approach, in that it is creating allogeneic iPSC-derived MSCs to be used for GvHD. There are also a number of companies specializing in iPSC product development, including Axiogenesis (a dominant European competitor), Axol Bioscience, ReproCELL, and others.
However, Cellular Dynamics International is one of the most important market participants, because of its dominance in both market areas. Furthermore, it was recently acquired by FujiFilm Holdings Corporation in April 2015, strengthening both its financial and strategic position.
It also recently divided into two equally important business units, a Therapeutics Business Unit and a Life Science business unit.
CDI’s new Therapeutics business unit focus on “developing and bringing to market induced pluripotent stem cell (iPSC)-based therapies in the ocular, cardiac, Parkinson’s, and oncology spaces, with IND applications in all these therapeutic areas expected in the 2018-2020 time period.” Its new Life Science business unit will concentrate on “building the research products business by propelling innovative cell products, applications, and services into the fast growing iPSC marketplace. This business unit is already on a clear path to profitability.”